Literature DB >> 23804121

Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection.

Christy M Tabarani1, Cynthia A Bonville, Manika Suryadevara, Patrick Branigan, Dongliang Wang, Danning Huang, Helene F Rosenberg, Joseph B Domachowske.   

Abstract

BACKGROUND: Virus-induced inflammation contributes to respiratory syncytial virus (RSV) pathogenesis. We sought to determine the specific mediators that are associated with more severe illness in young children.
METHODS: Children ≤ 5 years of age seen in our emergency department for respiratory symptoms from September 1998 to May 2008 were eligible for enrollment. Nasopharyngeal wash samples were collected from all eligible patients, and clinical data were recorded. Individuals were included in this study if nasopharyngeal wash samples were positive for RSV only. Patients enrolled in the study were stratified by disease severity, defined as mild (not hospitalized), moderate (hospitalized) or severe (requiring intensive care unit stay). Concentrations of individual inflammatory biomarkers in nasopharyngeal wash fluids were determined using the Luminex human 30-plex assay.
RESULTS: Eight hundred fifty-one patients met study criteria: 268 (31.5%) with mild, 503 (59.1%) with moderate and 80 (9.4%) with severe illness. As expected, illness severity was directly associated with young age, prematurity, heart or lung disease, infection with RSV group A and elevated concentrations of interleukin (IL)-2R, IL-6, CXCL8, tumor necrosis factor-α, interferon-α, CCL3, CCL4 and CCL2. In addition, we report several novel and mechanistically important inflammatory biomarkers of severe RSV disease, including IL-1β, IL1-RA, IL-7, epidermal growth factor and hepatocyte growth factor.
CONCLUSIONS: In a large, longitudinal study (10 years, 851 enrolled patients) limited to RSV infection only, in which well-known risk factors are confirmed, we identified 5 novel biomarkers specifically of severe disease. These markers may ultimately serve to elucidate disease mechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804121      PMCID: PMC3883981          DOI: 10.1097/INF.0b013e3182a14407

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  42 in total

1.  Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children.

Authors:  C B Hall; E E Walsh; K C Schnabel; C E Long; K M McConnochie; S W Hildreth; L J Anderson
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  Multicenter study of strains of respiratory syncytial virus.

Authors:  L J Anderson; R M Hendry; L T Pierik; C Tsou; K McIntosh
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

3.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.

Authors:  C J Holberg; A L Wright; F D Martinez; C G Ray; L M Taussig; M D Lebowitz
Journal:  Am J Epidemiol       Date:  1991-06-01       Impact factor: 4.897

4.  The proteins in nasal secretion: a longitudinal study of the gammaA-globulin, gammaG-globulin, albumin, siderophilin, and total protein concentrations in nasal washings from adult male volunteers.

Authors:  R D Rossen; A L Schade; W T Butler; J A Kasel
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

Review 5.  Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product.

Authors:  J S Rubin; D P Bottaro; S A Aaronson
Journal:  Biochim Biophys Acta       Date:  1993-12-23

6.  Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo.

Authors:  Allison L Miller; Terry L Bowlin; Nicholas W Lukacs
Journal:  J Infect Dis       Date:  2004-04-02       Impact factor: 5.226

7.  Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury.

Authors:  K Yanagita; K Matsumoto; K Sekiguchi; H Ishibashi; Y Niho; T Nakamura
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

8.  Respiratory syncytial virus infections in infants: quantitation and duration of shedding.

Authors:  C B Hall; R G Douglas; J M Geiman
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

9.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

10.  Respiratory syncytial virus (RSV) bronchiolitis: comparative study of RSV groups A and B infected children.

Authors:  S M Straliotto; B Roitman; J B Lima; G B Fischer; M M Siqueira
Journal:  Rev Soc Bras Med Trop       Date:  1994 Jan-Mar       Impact factor: 1.581

View more
  39 in total

1.  Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection.

Authors:  Caroline M Percopo; Michelle Ma; Todd A Brenner; Julia O Krumholz; Timothy J Break; Karen Laky; Helene F Rosenberg
Journal:  J Immunol       Date:  2018-12-21       Impact factor: 5.422

Review 2.  Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.

Authors:  Judy Chen; William J Kelley; Daniel R Goldstein
Journal:  J Immunol       Date:  2020-06-03       Impact factor: 5.422

3.  Altered Treg and cytokine responses in RSV-infected infants.

Authors:  Allison F Christiaansen; Muhammad A Syed; Patrick P Ten Eyck; Stacey M Hartwig; Lakshmi Durairaj; Sameer S Kamath; Steven M Varga
Journal:  Pediatr Res       Date:  2016-06-21       Impact factor: 3.756

4.  Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.

Authors:  Caroline M Percopo; Tyler A Rice; Todd A Brenner; Kimberly D Dyer; Janice L Luo; Kishore Kanakabandi; Daniel E Sturdevant; Stephen F Porcella; Joseph B Domachowske; Jesse D Keicher; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2015-07-02       Impact factor: 5.970

5.  Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma.

Authors:  Chaoyu Irvin; Iram Zafar; James Good; Donald Rollins; Christina Christianson; Magdalena M Gorska; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2014-07-18       Impact factor: 10.793

6.  β₂-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells.

Authors:  Sergio E Chiarella; G R Scott Budinger; Gökhan M Mutlu
Journal:  J Allergy Clin Immunol       Date:  2014-11-11       Impact factor: 10.793

7.  Sustained inflammation and differential expression of interferons type I and III in PVM-infected interferon-gamma (IFNγ) gene-deleted mice.

Authors:  Stephanie F Glineur; Aaron B Bowen; Caroline M Percopo; Katia E Garcia-Crespo; Kimberly D Dyer; Sergei I Ochkur; Nancy A Lee; James J Lee; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virology       Date:  2014-08-28       Impact factor: 3.616

8.  Differential Responses by Human Respiratory Epithelial Cell Lines to Respiratory Syncytial Virus Reflect Distinct Patterns of Infection Control.

Authors:  Philippa Hillyer; Rachel Shepard; Megan Uehling; Mina Krenz; Faruk Sheikh; Kalyn R Thayer; Lei Huang; Lihan Yan; Debasis Panda; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Raymond P Donnelly; Ronald L Rabin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

9.  Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway.

Authors:  Narayana Komaravelli; Maria Ansar; Roberto P Garofalo; Antonella Casola
Journal:  Free Radic Biol Med       Date:  2017-10-28       Impact factor: 7.376

10.  Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infection.

Authors:  Tyler A Rice; Todd A Brenner; Caroline M Percopo; Michelle Ma; Jesse D Keicher; Joseph B Domachowske; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2016-06-14       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.